-
Can't stop the bribery and drug rebate of many famous pharmaceutical enterprises, such as China Resources 39
Time of Update: 2020-01-16
Wen Liang Jian The bribery of hospital leaders and health officials by pharmaceutical companies has been prohibited for many times
Recently, China's official document
-
Hengrui invested nearly 100 million products and was approved to be listed in Germany
Time of Update: 2019-01-14
On January 11, Hengrui pharmaceutical announced that its subsidiary, cadiasun Pharma GmbH, had recently received an approval letter from the German Federal Institute of drugs and medical devices, which approved the listing application of the company's iodimethanol injection in Germany.
-
Xinji's 2017 financial report: lenalidomide's huge sale of $8.2 billion pounds, ozanimod is expected to go public in 2018
Time of Update: 2018-01-26
New base 2017 drug sales (US $100 million) Revlimid (lenalidomide) increased by 17% in 2017, reaching US $8.187 billion, thanks to the expansion of the market and the increase of medication schedule (promoted to MM first-line medication).
-
Biomedical market expands import substitution trend continues
Time of Update: 2017-10-10
[market analysis of chinapharma.com] according to the reports of marketsandmarkets, the global market size of contrast agents in 2016 is estimated to be 4.45 billion US dollars
-
Europe will become the next market for Aurobindo
Time of Update: 2017-07-05
Indian pharmaceutical companies have traditionally focused on API production and pharmaceutical production, so Aurobindo wants to improve the operational efficiency and cost of supply chain and distribution so as to increase opportunities for cooperation globally.
-
High incidence of cancer drug companies seize the highland of cellular immunotherapy
Time of Update: 2017-01-13
[China Pharmaceutical network industry trends] it is understood that the traditional treatment methods of cancer, such as surgery, radiotherapy and drug treatment, have certain
-
One minute review of July events in the pharmaceutical industry
Time of Update: 2016-08-04
Summary of major events in the pharmaceutical industry in July 2016 note: for details of major events, please refer to the historical push article of this month in pharmaceutical intelligence news.
-
Great turbulence, Shanghai pharmaceutical price linkage preliminary plan outflow
Time of Update: 2015-11-09
Source: Hushang Pharma 2015-11-09 according to the preliminary proposal of price linkage of Shanghai Pharmaceutical Market proposed by Shanghai Medical Insurance Department released by Hushang Pharma: start the dynamic adjustment of bidding drugs from the fourth quarter of this year.
-
Peier 13 surprised Pfizer with a 87% increase in sales in the second quarter
Time of Update: 2015-08-04
Previously, according to a recent report released by evaluate Pharma, a world-renowned pharmaceutical market research institution, Pfizer's pneumonia vaccine prevnar 13 will remain the world's best-selling vaccine product by 2020.
-
Sea of people tactics! India develops app to report drug black market and fake drugs
Time of Update: 2015-03-30
In recent years, with the special patent law in India, many pharmaceutical companies in India can quickly track the latest international generic drugs and export them at a very low price.
-
Medicine industry or meet the peak of restructuring
Time of Update: 2014-12-09
Source: Beijing business daily, 2014-12-09, M & A and restructuring among domestic pharmaceutical enterprises continued to heat up in 2014, and will reach a peak in the second half
-
Future trend of biopharmaceutical cro in 2015
Time of Update: 2014-11-05
1、 In 2015, the cro market scale reached $70 billion in biomedical outsourcing, which means that pharmaceutical companies engage in their own core business and transfer the non
-
Allergan rejects Valeant's $53 billion acquisition offer
Time of Update: 2014-06-12
Source: Allergan, June 11, 2014, said on Tuesday that its board of directors had unanimously rejected 530 from Valeant pharmaceuticals and Pershing square, Canada We believe
-
Allergan rejects Valeant's $53 billion acquisition offer
Time of Update: 2014-06-12
Source: Allergan said on Tuesday that its board of directors had unanimously rejected 530 from Valeant pharmaceuticals and Pershing square, a capital management company in Canada
-
The pharmaceutical industry in Europe and the United States announced that more data would be made public
Time of Update: 2013-07-29
The European Pharmaceutical Industry Alliance (EFPIA) and the American pharmaceutical research and Manufacturers Association (PhRMA) jointly said that they would open patient level clinical trial information to researchers.
